Corticosteroid News and Research

RSS

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

Soligenix's OrbeShield granted FDA oral BDP orphan drug designation

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) for the prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.

2 Jan 2013

Extended steroid treatment fails to reduce pediatric nephrotic relapse

Study findings indicate that extending initial prednisolone treatment durations in patients with pediatric nephrotic syndrome from 3 to 6 months without increasing the overall dose does not reduce the number of relapses.

22 Dec 2012

New once-daily dual bronchodilator effective in COPD

A once-daily, inhaled, fixed-dose dual bronchodilator combination has greater efficacy than twice-daily salmeterol plus fluticasone for the treatment of chronic obstructive pulmonary disease, results of the phase III ILLUMINATE trial show.

18 Dec 2012

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.

18 Dec 2012

God will control my asthma

Research shows that patients’ belief in God influences how likely they are to be adherent to asthma medication.

14 Dec 2012

High-altitude treatment may help severe asthma patients

Individuals with severe refractory asthma may benefit from high-altitude treatment, irrespective of their sensitivity to airborne allergens, suggest findings from a study conducted in the Swiss Alps.

11 Dec 2012

NICE reject intravitreal implant for diabetic macular edema

The UK National Institute for Health and Clinical Excellence has not recommended a fluocinolone acetonide intravitreal implant for individuals with diabetic macular edema who do not respond to existing therapies.

5 Dec 2012

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

30 Nov 2012

FDA grants final approval to Cobrek’s generic Luxiq foam NDA for treatment of scalp psoriasis

Perrigo Company today announced that its partner, Cobrek Pharmaceuticals, Inc., received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam.

28 Nov 2012

Azathioprine exposure concerns raised for SLE mothers

Researchers have raised the possibility of an increased risk for developmental delay in the children of mothers who used azathioprine for systemic lupus erythematosus during pregnancy.

26 Nov 2012

Nasal spray sufficient for allergic rhinitis in Japanese patients

Intranasal corticosteroid sprays can be administered as a first-line treatment for Japanese patients with seasonal allergic rhinitis, without the need to use systemic corticosteroid drugs, suggest study findings.

20 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Hydrocortisone protects bilateral knee replacement patients

Repeat doses of corticosteroids may protect patients undergoing bilateral total knee arthroplasty from postoperative side effects such as fever, pain, and acute respiratory distress, research suggests.

16 Nov 2012

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Soligenix, Inc., a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).

8 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Lupus may carry pregnancy complication risk

US researchers report that women with systemic lupus erythematosus have a twofold higher risk for developing preeclampsia than women without an autoimmune disease.

6 Nov 2012

Receptor expression sheds light on nasal polyposis

The increased expression of a leukotriene receptor and a glucocorticoid receptor may contribute to the development of nasal polyposis, report researchers.

6 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

World Prematurity Day: Nov. 17

This meeting organised in Paris from the 25th to the 27th of October, will be the opportunity to mark the end of inclusions for a cohort of over 8000 very preterm infants and to provide feedback on preliminary results of the project, launched in 2011.

26 Oct 2012